These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7797410)

  • 1. Magnetization transfer and high-dose contrast in early brain infection on magnetic resonance.
    Runge VM; Wells JW; Kirsch JE
    Invest Radiol; 1995 Mar; 30(3):135-43. PubMed ID: 7797410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detectability of early brain meningitis with magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM; Lee C; Timoney JF; Young AB
    Invest Radiol; 1995 Aug; 30(8):484-95. PubMed ID: 8557515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
    Runge VM
    Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of gadolinium-BOPTA on magnetic resonance imaging in brain infection.
    Runge VM; Wells JW; Williams NM; Timoney JF; Lee C
    Invest Radiol; 1996 May; 31(5):294-9. PubMed ID: 8724129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
    Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
    Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.
    Wolansky LJ; Finden SG; Chang R; Conigliari M; Lee HJ; Shaderowsky PD; Cook SD
    Clin Imaging; 1998; 22(6):385-92. PubMed ID: 9876905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
    Runge VM; Lee C; Iten AL; Williams NM
    Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
    Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
    AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral infarction: effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging.
    Mathews VP; King JC; Elster AD; Hamilton CA
    Radiology; 1994 Feb; 190(2):547-52. PubMed ID: 8284414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadoteridol dose dependence in MR imaging of a liver abscess model.
    Runge VM; Kirsch JE; Woolfolk C; Brack MA; Garneau RA
    J Magn Reson Imaging; 1994; 4(3):343-50. PubMed ID: 8061432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging of experimental pyelonephritis in rabbits.
    Runge VM; Timoney JF; Williams NM
    Invest Radiol; 1997 Nov; 32(11):696-704. PubMed ID: 9387058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.